Neil F. McFarlane's Net Worth
$2.68 Million
Who is Neil F. McFarlane?
Neil F. McFarlane has an estimated net worth of $2.68 Million. This is based on reported shares across multiple companies, which include ZEVRA THERAPEUTICS, INC., Retrophin, Inc., COLLEGIUM PHARMACEUTICAL, INC, and Adamas Pharmaceuticals Inc.
SEC CIK
Neil F. McFarlane's CIK is 0001681098
Past Insider Trading and Trends
2018 was Neil F. McFarlane's most active year for acquiring shares with 6 total transactions. Neil F. McFarlane's most active month to acquire stocks was the month of April. 2018 was Neil F. McFarlane's most active year for disposing of shares, totalling 4 transactions. Neil F. McFarlane's most active month to dispose stocks was the month of October. 2024 saw Neil F. McFarlane paying a total of $0.00 for 707,693 shares, this is the most they've acquired in one year. In 2018 Neil F. McFarlane cashed out on 21,125 shares for a total of $485,647.59, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ZEVRA THERAPEUTICS, INC. (ZVRA) Snapshot price: $7.26
President and CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Retrophin, Inc. (TVTX) Snapshot price: $10.98
Chief Operating Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -6.80% | -1.97K |
$18.25 | -$35,906.16 | 26.99K |
Scheduled
|
May 15 - May 16
| ||
Form 4
| -27.76% | -11.13K |
$22.32 | -$248,333.18 | 28.96K |
Scheduled
|
Dec 20
| ||
Form 4
| +38.42% | 11.13K |
—
|
—
| 40.08K |
Dec 18
| |||
Form 4
| -25.99% | -10.00K |
$23.73 | -$237,314.40 | 28.48K |
Scheduled
|
Nov 14
| ||
Form 4
| +35.12% | 10K |
—
|
—
| 38.48K |
Nov 9
| |||
Form 4
| +60.18% | 10.5K |
—
|
—
| 27.95K |
May 10
| |||
Form 4
| +17.08% | 2.55K |
—
|
—
| 17.45K |
Feb 8
| |||
Form 4
| -9.19% | -1.38K |
$22.50 | -$31,005.00 | 13.62K |
Aug 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 17
| |||
Form 4
|
∞
| 15K |
—
|
—
| 15K |
Aug 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
COLLEGIUM PHARMACEUTICAL, INC (COLL) Snapshot price: $37.19
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +18.46% | 7.69K |
—
|
—
| 49.37K |
May 16
| |||
Form 4
| +30.72% | 9.79K |
—
|
—
| 41.67K |
May 18
| |||
Form 4
| +78.65% | 14.04K |
—
|
—
| 31.88K |
May 19
| |||
Form 4
|
∞
| 17.84K |
—
|
—
| 17.84K |
Apr 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Adamas Pharmaceuticals Inc No price found
Chief Executive Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -525.00K |
—
|
—
|
0
|
Nov 24
| |||
Form 4
| +133.33% | 300K |
—
|
—
| 525K |
Mar 2
| |||
Form 4
| +80.00% | 100K |
—
|
—
| 225K |
Mar 18
| |||
Form 4
|
∞
| 125K |
—
|
—
| 125K |
Sep 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||